Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Pharmacol. 2013 Aug 15;714(1-3):325-31. doi: 10.1016/j.ejphar.2013.07.032. Epub 2013 Jul 30.

Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats.

Author information

1
Pharmacology Laboratory, Pharmaceutical Research Laboratories, Toray Industries, Inc., Kanagawa 248 8555, Japan. Shinichi_Yamaguchi@nts.toray.co.jp

Abstract

Beraprost sodium, a stable prostacyclin analog, was showed to improve survival rates in two different rat models, anti-glomerular basement membrane (GBM) glomerulonephritis (GN) and 5/6 nephrectomized (Nx) chronic kidney disease (CKD) rats. In the anti-GBM rat, beraprost sodium (0.2 and 0.6 mg/kg/day) improved survival rate (hazard ratio for beraprost sodium 0.6 mg/kg/day group, 0.10; 95% confidence interval, 0.01 to 0.68). Subsequently, in the 5/6 Nx CKD rat, beraprost sodium (0.6 mg/kg/day) improved survival rate (hazard ratio for beraprost sodium, 0.46; 95% confidence interval, 0.23 to 0.92), serum creatinine doubling time and the slope of the reciprocal of serum creatinine. In the anti-GBM GN rats, beraprost sodium suppressed the serum accumulation of representative uremic toxins such as indoxyl sulfate. Furthermore, beraprost sodium inhibited human aortic endothelial cell (HAEC) injury induced by indoxyl sulfate, indicating that beraprost sodium might have a protective effect against cardiovascular damage due to CKD. These results show that beraprost sodium can improve the survival rates in two rat models of anti-GBM GN and 5/6 Nx CKD rats by protecting endothelial cells and thereby ameliorating decreased renal function. Therefore, clinical studies are needed in patients with chronic kidney failure to determine whether beraprost sodium will become a useful medication in CKD.

KEYWORDS:

5/6 nephrectomized; Anti-glomerular basement membrane glomerulonephritis; Beraprost sodium; Chronic kidney disease; Endothelial cell protection; Indoxyl sulfate; Survival rate; Uremic toxin

PMID:
23911885
DOI:
10.1016/j.ejphar.2013.07.032
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center